Novel target and treatment agents for natural killer/T-cell lymphoma

Table 4 Summary of signaling pathway inhibitors and ongoing clinical trials in NKTCL patients

Signaling pathway inhibitors	Target	Trial ID	Number of estimated enrollment	Study phase	Combined agents	Indication	Results for NKTCL	References
Bortezomib	NF-κB	NCT02808091	7	2	GIFOX	Newly diagnosis NKTCL	ORR:43%	[95]
Anlotinib	VEGFR	NCT04004572	37	2	Sintilimab Pegaspargase	Stage IV NKTCL	/	/
Apatinib	VEGFR2	NCT04366128	60	NA	Camrelizumab Pegaspargase	Stage IE/IIE ENKTL	/	/
Avastin (Bevacizumab)	VEGF	NCT01921790	30	2	GemAOD	Untreated NKTCL	/	/
Tofacitinib	JAK1/3	NCT03598959	20	2	Chidamide	r/r NKTCL	/	/
Ruxolitinib	JAK1/2	NCT02974647	82	2		r/r NKTCL	/	/
Selinexor (ATG-010)	XPO1	NCT04425070	97 (10 NKTCL)	1/2	GemOx or ICE or Tislelizumab	Peripheral T- and NK/T-cell lymphoma	ORR: 60% CR: 20%	[109]

NKTCL: natural killer/T-cell lymphoma, GIFOX: gemcitabine, ifosfamide and oxaliplatin, ORR: objective response rate, CR: complete remission, GemAOD: gemcitabine, oxaliplatin, pegaspargase and dexamethasone, VEGFR: vascular endothelial growth factor receptor, VEGF: vascular endothelial growth factor, NA: not available, JAK: Janus-associated kinase, NF-κB: nuclear factor κB, ENKTL: extranodal natural killer/T-cell lymphoma, XOP1: exportin-1, GemOx: gemcitabine and oxaliplatin, ICE: ifosfamide, carboplatin and etoposide

ISSN: 1756-8722